Lionsgate (LGF): Cutting 2Q Estimates But Not Rating - B.Riley
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
B. Riley analyst, Eric Wold, reiterated his Buy rating on shares of Lions Gate (NYSE: LGF) but is cutting 2Q estimates. The opening for Deepwater Horizon puts the film on-track to exceed expectations but will mostly benefit Q3 results. The analyst is cutting Q2 estimates with final the box office in the books and while a handful of films disappointed in Q2, this does not derail the positive thesis on either 1) an expectation for more stabilized results for standalone LGF with a diversified film slate and ramping TV production revenues; or 2) the strategic benefits of the LGF/STRZA combination.
No change to the price target of $34.
Shares of Lions Gate closed at $19.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Union Pacific (UNP) PT Raised to $102 at Stifel Following 4Q Report
- JPMorgan Cuts Teva Pharma (TEVA) to Neutral Amid Challenging Generic Environment
- Polaris Industries (PII) PT Raised to $85 at Stifel Ahead of 4Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change
Related EntitiesB. Riley
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!